NICE green light for Eylea in mCNV

The UK’s medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has provided final positive recommendation for Eylea (aflibercept solution for injection) for adults for the treatment of visual impairment due to myopic chorodial neovascularization (mCNV). The ophthalmic drug is already a blockbuster for Germany’s Bayer (BAYN: DE).

Lars Bruening, chief executive if Bayer UK/Ireland, commented: “We are pleased that NICE has recognized the value of Eylea and the benefits that it can bring to patients and the clinical community. At Bayer we are committed to ensuring all eligible patients have access to Eylea in line with the market authorization so it is great news for patients with mCNV in England and Wales who will have access to this effective treatment as soon as adopted by policy makers.”

Eylea is licensed in the UK for the treatment of wet age-related macular degeneration (wAMD); visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) and visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO); visual impairment due to diabetic macular edema (DMO) and myopic choroidal neovascularization (mCNV).